TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
News|Podcasts|June 4, 2025
The Weekly Dose: Advancements in Colonoscopy, AI for Mammography, and Telemedicine Antibiotic Stewardship
Author(s)Sydney Jennings
Fact checked by: Grace Halsey
Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.
Advertisement
In this episode of Weekly Dose, we round up the latest clinical research, featuring key studies on patient navigation for follow-up colonoscopy, the FDA-approved Teal Wand for at-home cervical cancer screening, and the effectiveness of telemedicine in managing acute respiratory tract infections. We also explore the real-world data on upadacitinib for Crohn's disease and the impact of AI in improving mammography accuracy. Tune in for a comprehensive look at these groundbreaking studies and their implications for clinical practice.
Advertisement
Related to this article
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.
In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
3
JoAnn Pinkerton, MD, on Counseling Patients Starting Elinzanetant for VMS
4
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
5